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Abstract
Background The aim of the study was to evaluate the
efﬁcacy and safety of combined treatment with natural
leukocyte interferon alpha (Alfaferone) plus ribavirin in
patients with HCV-related cirrhosis.
Patients and methods Twenty-three patients (15 women,
8 men) aged 17–68 years hospitalized in 2005–2008 were
included in the study. Seventeen patients who qualiﬁed for
treatment were Child-Pugh class A patients and 6 others
were class B. Seventeen patients had genotype 1b and 6
genotype 3a infection. Thirteen patients were naı ¨ve, re-
therapy concerned 8 patients, and in two cases the con-
tinuation of treatment had been stopped because of adverse
events following the use of pegylated interferons. The
treatment was continued for 48 weeks regardless of HCV
genotype. Normalized AlAT activity (\40 U/l) was the
measure of biochemical efﬁcacy of the treatment, while
virological efﬁcacy was reﬂected by an undetectable viral
load in plasma. Both measurements were conducted
immediately after the end of treatment (EOT) and after a
6-month follow-up period (SVR). Therapeutic safety was
evaluated by the monitoring of the adverse events of the
treatment.
Results Abnormal AlAT levels prior to treatment were
detected in 20/23 patients. During therapy normalized
levels were achieved in 50% of them, and after 6 months
they were sustained in 9/20. EOT was achieved in 6/19
patients and SVR in 3 patients. Mild psychiatric disorders
were the most frequently detected adverse events (12
patients). Thrombocytopenia and leucopenia existing prior
to treatment did not intensify during the treatment. Severe
adverse events caused by the drug resulted in the discon-
tinuation of treatment in three patients (urinary tract
infections, depression, myasthenia gravis), of whom two
patients were Child-Pugh class A and one was class B. In
one patient treatment was discontinued because of HCC.
Conclusion Natural leukocyte interferon alpha is well
tolerated by patients with HCV-related cirrhosis and
coexisting thrombocytopenia and leucopenia.
Keywords Adverse events  Cirrhosis  Natural leukocyte
interferon alpha  Sustained virological response
Introduction
The combination of pegylated interferon and ribavirin is
the current standard treatment for chronic HCV infections
[1]. Other interferons may be administered when the
pegylated interferon therapy is contraindicated or when
adverse events of this treatment are present (e.g., cytopenia
during the already initiated treatment). This is particularly
important in patients with cirrhosis, where neutro- and
thrombocytopenia are frequently observed [2]. In clinical
practice these problems are considered a criterion dis-
qualifying patients from treatment [1]. In such cases an
attempt can be made to treat patients with natural leukocyte
interferon alpha, a blend of different interferon types with
complementary activity. As a consequence, interferon
alpha is the ﬁrst choice drug in the discussed cases.
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DOI 10.1007/s15010-011-0135-3This paper presents our experience in the use of natural
leukocyte interferon alpha (Alfaferone) combined with
ribavirin in the treatment of patients with HCV-related
cirrhosis. This concerned naı ¨ve patients, re-therapy, and the
continuation of previous treatment that had been discon-
tinued because of adverse events.
Materials and methods
Twenty-three patients with HCV-related cirrhosis treated
in the Department of Infectious Diseases and Hepatology
in Bydgoszcz, Poland, in 2003–2008 were included in the
study. This group comprised 15 women and 8 men aged
17–68 years (average 52 years). The average body mass of
patients was 77.6 kg (57.5–114 kg). Characteristics of the
patients are presented in Table 1.
Hepatitis C virus RNA was detected based on the results
of RT PCR tests. We analyzed the levels of baseline
viremia and its kinetics in the course of therapy. We
detected 17 infections with genotype 1b HCV and 6
infections with genotype 3a HCV.
Cirrhosis was diagnosed based on generally accepted
clinical, biochemical and histological criteria. Seventeen
Child-Pugh class A patients and 6 Child-Pugh class B
patients were qualiﬁed for the treatment. Classiﬁcation into
Child-Pugh class B was determined by elevated bilirubin
levels of up to 2–3 mg/dl (3 patients), reduction of albumin
levels down to 3.5–2.8 g/dl (3 patients), prothrombin time
elongation (6 patients), and/or ascites (3 patients). Patients
with peritoneal ﬂuids present were treated with diuretics
until the condition was resolved. Twenty of 23 patients had
increased activity of alanine aminotransferase (50–408 U/l,
average level 150 U/l). Five patients were diagnosed with
esophageal varices, of whom two were treated with beta-
blockers and three with endoscopic banding ligation.
Each patient who met the criteria for the therapy was
monitored for hepatocellular carcinoma (HCC). Prior to
treatment and every 3 months patients were examined by
abdominal ultrasound scan, and the level of alpha-feto-
protein (AFP) in plasma was measured. When test results
were uncertain, diagnostic methods were complemented
with abdominal computer tomography (CT). Qualiﬁcation
of patients for therapy included repeated psychiatric con-
sultation during the course of therapy.
The discussed group of patients consisted of 13 naı ¨ve
patients and 8 patients who were being treated because of
ineffective previous treatment. In two cases the treatment
was a continuation of previous treatment with pegylated
interferon that had been discontinued because of adverse
events of the drug treatment (leucopenia with coexisting
hyperthyreosis and thrombocytopenia).
Alfaferone (Alfaferone
; ALFA WASSERMANN,
Bologna, Italy) was used in a dose of three million units,
three times a week, by subcutaneous injection. Ribavirin
(Rebetol
; Schering-Plough, Kenilworth, NJ) was admin-
istered orally in a daily dose of 800–1,200 mg, depending
on body mass. Five of 23 patients were initially treated
with ribavirin doses lower than that suggested by their
body mass. This was due to starting hemoglobin levels of
10–11 g/dl and was dictated by patient safety consider-
ations. Three out of those ﬁve patients were classiﬁed into
Child-Pugh class A. The treatment was continued for
48 weeks regardless of HCV genotype. Therapeutic efﬁ-
cacy was assessed based on the level of HCV viremia
directly after the end of treatment (EOT) and after a further
24 weeks sustained virological response (SVR) and subsi-
dence of the previous biochemical activity of the disease.
Adverse events associated with the treatment were
analyzed based on clinical observations and laboratory
tests conducted at 2-week intervals. The effect of Alfaf-
erone on thrombocytopenia and leukopenia detected prior
to treatment was analyzed.
Table 1 Characteristics of the patient population
Sex (female/male) 15/8
Age (years) (average) 17–68 (52)
Child-Pugh score
A1 7
B6
Weight (kg) (average) 57.5–114 (76)
Duration of treatment (weeks) 48
First treatment with LeIFN
alpha ? RBV
13
Continuation with LeIFN alpha after
PegIFN 2a/2b
2
Retreatment with LeIFN alpha ? RBV 8
IFN preparation
rIFN 2b 1
rIFN2b ? RBV 1
PegIFN 2a ? RBV 4
PegIFN 2b ? RBV 2
HCV genotype
1b 17
3a 6
Pretreatment HCV RNA levels (IU/ml)
(average)
3.75 9 10
3–1.92 9 10
7
(3.33 9 10
6)
Pretreatment AlAT levels (U/l)
3 patients Normal
20 patients 50–408 (150)
EOT 6
SVR 3
EOT end of treatment response, SVR sustained virological response,
rIFN 2b recombinant interferon alpha 2b, LeIFN alpha natural leu-
kocyte interferon alpha, RBV ribavirin, PegIFN 2a/2b pegylated
interferon alpha 2a/2b
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123AFP level was measured with the chemiluminescence
method using the LIAISON AFP test from DiaSorin (ref-
erence values up to 5.5 IU/ml) (Humor Diagnostica, South
Africa).
The activity of alanine aminotransferase (AlAT) was
measured using the ICFF method without pyridoxal phos-
phate at a temperature of 37C using a test kit from Roche
and the Cobas Integra analyzer. Correct levels were below
40 U/l, regardless of sex.
HCV RNA was detected with RT PCR at the method’s
linearity of 43–6.9 9 10
7 IU/ml using the COBAS Am-
pliPrep/COBAS TaqMan HCV test (HCMCAP) reagent
from Roche Diagnostic (Indianapolis, IN), while the HCV
genotype was detected by hybridization with Linear Array
HCV Genotyping Test (LA HCV GT) reagents from
Roche.
Platelet and leukocyte levels were measured with the
conductometric method on a Sysmex K-4500 analyzer
(Sysmex Corp., Japan), and the ratio of leukocyte sub-
populations was measured based on blood smear in a
microscopic specimen stained using the May-Gru ¨nvald,
Giemsa method.
Results
Nineteen of 23 patients successfully completed the planned
treatment. EOT was achieved in six patients (ﬁve Child-
Pugh class A patients and one Child-Pugh class B patient).
Five patients were infected with a genotype 1b virus and
one patient with genotype 3a. Three patients in which a
virological response was achieved at the EOT were naı ¨ve
patients. Another one patient was in a re-treatment group,
and in two patients Alfaferone and ribavirin therapy was
the continuation of previous treatment with pegylated
interferon. SVR was achieved in three patients (all Child-
Pugh class A). All patients were infected with genotype 1b.
SVR was achieved in 1/13 naı ¨ve patients and in two
patients where Alfaferone was used instead of pegylated
interferon.
AlAT was normalized during the treatment in 10 out of
20 patients who demonstrated elevated biochemical activ-
ity prior to treatment, and in 9 cases it was sustained during
a 6-month follow-up period.
Treatment was discontinued in four patients. In three
cases this was due to adverse events caused by the drug,
and in one patient it was due to diagnosed HCC. The
patient with HCC was sent to the transplantation ward
where qualiﬁcation to liver transplant was started. Adverse
events disqualifying patients from further treatment inclu-
ded intensiﬁed depression, myasthenia gravis and urinary
tract infections that led to decompensation of hepatic
function in one Child-Pugh class B patient. Other patients
were qualiﬁed to class A.
Other most frequently recorded adverse events were
psychiatric disorders, reﬂected by impaired mental func-
tion, sleep disorders, mood swings, neurasthenia, and
depressive syndromes. Two patients were diagnosed with
infections: one patient had recurrent labial herpes, and the
other had a urinary tract infection. Adverse events fre-
quently coexisted. Most adverse events were observed in
Child-Pugh class A patients. Stable angina pectoris was
diagnosed in one Child-Pugh class B patient, and depres-
sive disorders were diagnosed in another two Child-Pugh
class B patients.
Adverse events and the reasons for premature discon-
tinuation of natural leukocyte interferon alpha treatment
are presented in Table 2.
Eight of 23 patients had leucopenia befor Alfaferone and
ribavirin treatment. None of the ﬁve patients with absolute
neutrophil counts below 1,500/mm
3 required a reduced
dose of Alfaferone for longer than 2 weeks (Table 3).
Table 2 Adverse events and
reasons for premature
discontinuation of treatment
with natural leukocyte
interferon alpha
Adverse events caused
by Alfaferone
Total number of cases/
Child-Pugh score (A/B)
Number of prematurely
discontinued treatments
(Child-Pugh score)
Psychiatric disorders 12/(10/2) 1 (A)
General weakness 7/(7/0) –
Flu-like symptoms 3/(2/1) –
Skin lesions 3/(3/0) –
Infections 3/(2/1) 1 (B)
Visual disorders 1/(0/1) –
Angina pectoris, stable 1/(0/1) –
Hyperthyroidism 1/(1/0) –
Hair loss 1/(1/0) –
Myasthenia gravis 1/(1/0) 1 (A)
HCC 1/(1/0) 1 (A)
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17 patients with thrombocytopenia below 90,000/ll, which
would have required modiﬁcation of interferon dosage
(Table 4).
During treatment the dosage of ribavirin was reduced in
ten patients because of decreased hemoglobin levels below
10 g/dl and/or clinical symptoms of anemia, decreased
tolerance of physical effort, or vertigo.
Discussion
Alfaferone is highly puriﬁed interferon alpha containing 18
interferon subtypes derived from human leukocytes [3]. A
few research papers on the use of Alfaferone in the treat-
ment of patients with HCV-related cirrhosis have been
published so far [4–7].
Patients with cirrhosis are classiﬁed as ‘‘difﬁcult to
treat.’’ Aghemo et al. in their study emphasized that
treatment based on pegylated interferon alpha 2b in
patients with cirrhosis infected with genotypes 1, 3, and 4
HCV yielded signiﬁcantly less SVR than in patients
without cirrhosis (genotypes 1 and 4: 17 vs. 36%; genotype
3: 33 vs. 79%). Relapses were observed more frequently in
cirrhotic patients (genotypes 1 and 4: 55 vs. 31%; genotype
3: 61 vs. 12%) [8]. Our study conﬁrmed these ﬁndings as
SVR was achieved in three patients. In addition, factors
responsible for treatment failure particularly include high
baseline viremia ([800,000 IU/ml), body mass over 75 kg,
age over 40 years during infection, HIV/HCV coinfection,
and previous ineffective treatment [9–11]. These factors,
except for HIV infection, frequently coincided in the
studied group of patients. Treatment efﬁcacy also depends
on ribavirin dose [1, 12]. Some patients from the study
group required reduced doses of ribavirin, which may have
affected the treatment outcomes.
Alfaferone was tolerated well by patients with hemato-
logical disorders, and patients with contraindications
against using other interferon types were treated (throm-
bocytopenia \90 9 10
3/ll, neutropenia \1,500/mm
3).
Thrombocytopenia did not intensify signiﬁcantly during
treatment. Even in patients with platelet levels below
30,000/ll, no clinical symptoms of thrombocytopenia were
detected, and in none of them was treatment discontinued
Table 3 The effect of
Alfaferone on leucopenia
existing prior to treatment
a Leukocytes—normal range
4–10 9 10
3/ll
Patient no. Initial levels
a Minimum level
during therapy
Levels in 48th
week of treatment
Leukocytes
(910
3/ll)
Neutrophils Leukocytes
(910
3/ll)
Neutrophils Leukocytes
(910
3/ll)
Neutrophils
1 3.1 2,046 1.8 972 2.3 1,518
2 1.7 697 1.7 697 – –
3 2.0 1,080 1.9 1,121 2.6 1,898
4 2.1 1,000 2.1 1,000 2.6 1,100
5 2.5 800 1.5 555 2.3 810
6 2.2 1,500 1.2 840 2.9 1,800
7 3.1 2,263 1.6 843 2.1 1,176
8 3.7 2,150 2.9 1,800 3.3 1,500
Table 4 The effect of Alfaferone on platelets level existing prior to
treatment
Patient
no.
Initial platelet
levels (910
3/ll)
a
Minimum
platelet levels
during treatment
(910
3/ll)
Platelet levels
in 48th week
of treatment
(910
3/ll)
15 4 5 4 8 2
22 7 2 7 5 1
36 2 3 8 5 7
45 7 4 9 5 9
5 74 74 101
65 3 – –
74 4 4 4 5 5
84 6 3 2 3 0
9 53 53 280
10 68 50 50
11 65 64 82
12 51 42 51
13 20 17 18
14 29 24 34
15 86 38 51
16 65 48 69
17 19 17 56
18 53 139 280
19 132 154 219
20 208 142 169
21 100 75 94
22 126 102 151
23 161 85 158
a Platelets—normal range 150–350 9 10
3/ll
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123for this reason. These ﬁndings conform with reports by
other authors and with our previous studies [5, 13–17].
Psychiatric disorders observed during the treatment
based on natural leukocyte interferon alpha were mild,
except for in one patient, and were successfully managed
by psychotherapeutic and pharmacological methods.
Infections were not diagnosed in patients with neutropenia.
In the patient who developed HCC, HCV viremia was
never undetectable during the treatment. Similar observa-
tions were made by Ferrara et al. [18]. Standard therapy
with pegylated interferon plus ribavirin is recommended
only in Child-Pugh class A patients [1]. Alfaferone can also
be used, as demonstrated by our own experience, in class B
patients. We did not observe differences in the frequency
of adverse events or lower tolerance to treatment between
Child-Pugh patients class B and class A. Patients with
HCV-related cirrhosis are potential candidates for liver
transplant, and for this reason antiviral treatment should be
applied prior to surgical procedures [1]. In patients with
liver cirrhosis if there is no option for optimal therapy with
pegylated interferon plus ribavirin because of cytopenias,
for example, the use of natural leukocyte interferon alpha
plus ribavirin should be considered.
Conclusions
1. Although the data are very limited (23 patients),
treatment with natural leukocyte interferon alpha
(Alfaferone) plus ribavirin in patients with HCV-rela-
ted cirrhosis seems to be safe.
2. Alfaferone administered in patients with thrombocy-
topenia and neutropenia did not exacerbate these
hematological disorders and caused no threat to life.
3. Alfaferone was well tolerated by both Child-Pugh
class A and class B patients.
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